Previous studies reported that RHEBL1 could function as an activator of NF-kB [17] and mTOR [30] signaling, both of which are frequently altered in many solid tumors, as well as in leukemias and lymphomas[27, 31-36]. This evidence concerns the gene NFKB1 and leukemia.